Unravelling the puzzle of antithrombotic therapies for complex percutaneous coronary intervention

Eur Heart J Cardiovasc Pharmacother. 2021 Jul 23;7(4):352-359. doi: 10.1093/ehjcvp/pvaa107.

Abstract

Percutaneous coronary intervention (PCI) has remarkably evolved in the last decades. This has resulted in a larger number of patients treated with PCI, including those with more complex anatomic lesions. Several studies demonstrated that PCI involving complex lesions is associated with increased rate of procedural complications and adverse clinical outcomes. In this setting, optimal adjunctive antithrombotic regimens still need to be defined. In this review, we sought to summarize and discuss the recent evidence deriving from analyses appraising antithrombotic therapies in patients undergoing complex PCI.

Keywords: Anticoagulation therapy; Aspirin; Cangrelor; Clopidogrel; Complex PCI; Dual antiplatelet therapy; Rivaroxaban; Ticagrelor; Unfractioned heparin.

Publication types

  • Review

MeSH terms

  • Drug Therapy, Combination
  • Fibrinolytic Agents* / adverse effects
  • Humans
  • Percutaneous Coronary Intervention* / adverse effects

Substances

  • Fibrinolytic Agents